Sculptor Capital’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Sculptor Capital’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-352,907	Closed	-$3.56M	–	844
2022 Q4	$3.56M	Hold	352,907	–	–	0.06%	292
2022 Q3	$3.5M	Hold	352,907	–	–	0.04%	429
2022 Q2	$3.46M	Sell	352,907 -9,711	-3%	-$95K	0.04%	475
2022 Q1	$3.53M	Buy	362,618 +162,620	+81%	+$1.58M	0.03%	509
2021 Q4	$1.94M	Hold	199,998	–	–	0.02%	600
2021 Q3	$1.93M	Hold	199,998	–	–	0.02%	486
2021 Q2	$1.95M	Buy	+199,998	New	+$1.96M	0.01%	524

Sculptor Capital's EBAC Position: Q1 2023 in Review

Sculptor Capital sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 352,907 shares — an estimated $3.56M sold.

Sculptor Capital first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $3.56M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Sculptor Capital reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Sculptor Capital sold 352,907 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $3.56M.
Sculptor Capital first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Sculptor Capital's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $3.56M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Sculptor Capital's 13F filing for Q1 2023, filed 16 May 2023.